Wave Life Sciences Ltd Expected To Post A Loss Of 28 Cents A Share: Earnings Preview

Wave Life Sciences

08/11/2024 17:14

* WAVE Life Sciences Ltd  WVE.OQ   WVE.O  is expected
to show a
fall in quarterly revenue when it reports  results on November
12 for the period ending September 30 2024
    * The  Singapore-based   company is expected to report a
65.6% decrease in revenue to $16.947 million from $49.21 million
a year ago, according to the mean estimate from 10 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for WAVE Life Sciences Ltd
is for
a loss of 28 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 9 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for WAVE Life
Sciences Ltd is $21.00​, above​ its last closing price
of $14.83. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jun. 30 2024  -0.19       -0.21      -0.25     Missed  -21
 Mar. 31 2024  -0.17       -0.21      -0.24     Missed  -12.1
 Dec. 31 2023  -0.13       -0.23      -0.15     Beat    33.8​
 Sep. 30 2023  -0.11       -0.18      0.07      Beat    139.3
 ​​Jun.        -0.32       -0.33      -0.20     Beat    39.7
 30 2023                                                
 Mar. 31 2023  -0.17       -0.04      -0.27     Missed  -575​
 Dec. 31 2022  -0.47       -0.41      -0.47     Missed  -14.6
 Sep. 30 2022  -0.50       -0.50      -0.42     Beat    15.4
 This summary was machine generated November 8 at 17:14 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)